CN101322826B - Chinese medicine for treating cholecystitis and method of preparing the same - Google Patents
Chinese medicine for treating cholecystitis and method of preparing the same Download PDFInfo
- Publication number
- CN101322826B CN101322826B CN2008101344557A CN200810134455A CN101322826B CN 101322826 B CN101322826 B CN 101322826B CN 2008101344557 A CN2008101344557 A CN 2008101344557A CN 200810134455 A CN200810134455 A CN 200810134455A CN 101322826 B CN101322826 B CN 101322826B
- Authority
- CN
- China
- Prior art keywords
- weight
- radix
- medicine
- cholecystitis
- weight portion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The invention relates to a traditional Chinese medicine used for curing cholecystitis and a preparation method thereof, in particular to a traditional Chinese medical composition used for curing acute and chronic cholecystitis and a preparation method thereof. The medicine of the invention solves the unnecessary damage caused by past medicines for curing the cholecystitis to the liver of human body, further improves the immunity of the human body and enhances the curative effect.
Description
Technical field
The present invention relates to a kind of cholecystitis Chinese medicine its preparation method that is used for the treatment of, especially for Chinese medicine composition for the treatment of acute and chronic cholecystitis and preparation method thereof.
Background technology
Cholecystitis is modal gallbladder disease, and normal and cholelithiasis exists simultaneously.The women is more than the male.Cholecystitis is divided into acute and chronic two kinds, and modern medicine thinks how the cause of disease of cholecystitis causes by blocking factor, infective agent, chemical factor etc.At present, the treatment cholecystitis especially treat the various medicines of acute and chronic cholecystitis existing several, especially the therapeutic effect that brings of Chinese medicine medicine has brought Gospel for the cholecystitis patient, cures and solved the misery of extensive patients.The treatment principle of Chinese traditional treatment cholecystitis is essentially: depressed liver-energy dispersing and function of gallbladder promoting, heat-clearing and toxic substances removing, anti-inflammatory and choleretic, Chinese herbal medicine have become the main flow medicine of modern Chinese medicine treatment cholecystitis.But, still exist among the patient group at present, because the cholecystitis disease can not thoroughly be cured for a long time, cause showing effect repeatedly, thereby also can cause the not normal initiation of the normal physiological function complication of other relevant internal organs simultaneously, cause diseases such as bile adverse current gastritis such as causing gastropyloric systolic and diastolic function disorder.Disclosed a kind of Chinese herbal medicine formula for the treatment of cholecystitis among the patent application CN1364626A, the proportioning consumption of used Herba Lysimachiae, Radix Gentianae, Radix Et Rhizoma Rhei is big slightly among its side, for the critical or more weak patient of body constitution, can cause certain side effect, the human liver is caused unnecessary damage, thereby influence its final therapeutic effect.
Summary of the invention
The present invention only pays attention to depressed liver-energy dispersing and function of gallbladder promoting, heat-clearing and toxic substances removing, the existing deficiency of this principle of anti-inflammatory and choleretic and a kind of Chinese medicine medicine for the treatment of cholecystitis of proposing at modern Chinese medicine treatment cholecystitis, except paying attention to above principle, simultaneously also affix effects such as hepatoprotective, circulation of qi promoting dissipating blood stasis, promoting the circulation of QI to relieve pain, promoting digestion and removing stagnation, promoting the function of the gallbladder to alleviate jaundice, more main is to the present invention is to provide a kind of cure rate height, more the back is difficult for the Chinese medicine of the treatment cholecystitis of recurrence, effects such as it has protecting the liver, improves immunity, anti-inflammation, promotion bile secretion and drainage.
Technical scheme of the present invention is: a kind of Chinese medicine composition for the treatment of cholecystitis, especially a kind of Chinese medicine medicine for the treatment of acute and chronic cholecystitis, be by the Radix Aucklandiae, Radix Curcumae, Fructus Aurantii, Radix Et Rhizoma Rhei, Herba Artemisiae Scopariae, Fructus Crataegi, Massa Medicata Fermentata, Radix Gentianae, Herba Lysimachiae, Fructus Hordei Germinatus (parched), Rhizoma Atractylodis Macrocephalae (parched) ten simply crude drug make, wherein:
Radix Aucklandiae 10-30 weight portion, Radix Curcumae 15-35 weight portion, Fructus Aurantii 15-35 weight portion, Radix Et Rhizoma Rhei 5-20 weight portion, Herba Artemisiae Scopariae 30-60 weight portion, Fructus Hordei Germinatus (parched) 15-35 weight portion, Fructus Crataegi 20-50 weight portion, Massa Medicata Fermentata 15-35 weight portion, Radix Gentianae 10-25 weight portion, Herba Lysimachiae 10-30 weight portion, Rhizoma Atractylodis Macrocephalae (parched) 20-50 weight portion.
Wherein each crude drug weight proportion is preferably:
The Radix Aucklandiae 20 weight portions, Radix Curcumae 25 weight portions, Fructus Aurantii 25 weight portions, Radix Et Rhizoma Rhei 10 weight portions, Herba Artemisiae Scopariae 50 weight portions, Fructus Hordei Germinatus (parched) 25 weight portions, Fructus Crataegi 30 weight portions, Massa Medicata Fermentata 25 weight portions, Radix Gentianae 15 weight portions, Herba Lysimachiae 20 weight portions, Rhizoma Atractylodis Macrocephalae (parched) 30 weight portions.
Making of medicine of the present invention by following preparation method:
Take by weighing above-mentioned materials of weight proportions medicine, the selected roguing of medical material, porphyrize is crossed 120 mesh sieves respectively, adds the auxiliary materials and mixing packing and makes powder;
Take by weighing above-mentioned materials of weight proportions medicine, the selected roguing of medical material, water or alcoholic solution that adding 5-10 doubly measures soaked 5-10 hour, concentrated and made extractum, were equipped with corresponding excipient, made peroral dosage forms such as pill, tablet, capsule respectively.
The concrete compatibility principle and the drug effect of medicine of the present invention are as follows:
The Radix Aucklandiae: this product contains nearly 20 seed amino acids and cholamine compositions such as volatile oil, saussurine, costol, constuslactone, have economic benefits and social benefits and regulate gastrointestinal function, can make the intestinal smooth muscle excitement, enterokinesia amplitude and myenteron tension force obviously strengthen, by antibacterial and antibacterial action, inhibited to streptococcus, golden yellow, Staphylococcus albus, escherichia coli.The Radix Aucklandiae has the effect of promoting the circulation of QI to relieve pain, strengthening the spleen to promote digestion, 'Shugan Lidan '.
Radix Curcumae: the Radix Curcumae tuber mainly contains volatile oil; comprise demethoxycurcumin, turmerone; in addition starch-containing, fatty oil, methyl methylol curcumin; obvious promotion bile secretion and drainage, excited intestinal tube are arranged; protection gastrointestinal mucosa, protection hepatocyte; promote liver cell regeneration, degrease and the Fibrotic effect of inhibition hepatocyte.Effect with dispersing the stagnated live-QI to relieve the stagnation of QI, promoting the circulation of QI to relieve pain, promoting the function of the gallbladder to alleviate jaundice.
Fructus Aurantii: bitter in the mouth, suffering, acid, cold nature.Return spleen, stomach warp.Regulating the flow of QI to ease the stomach is arranged, functions such as the stagnant relieving distension of row.Be used for the breast side of body stagnation of QI, distension pain, accumulation of food in the stomach and intes tine due to indigestion stops in the phlegm retention, diseases such as gastroptosis.Main component: sour orange peel contains hesperidin, neohesperidin, Nobiletin, 5-neighbour-demethylnobiletin, quinolizidine morpholine, narcotine, norepinephrine, tryptamines, tyramine, Neosynephrine and N-methyltyramine.Contain neohesperidin, naringin, hesperidin, rhoifolin, limonene, capraldehyde, aldehyde C-9, dodecanal, acetic acid Lignum cinnamomi camphorae oil, acetic acid orange blossom fat, acetic acid Herba Pelargonii Graveolentis fat etc. in the underdone peel of CitrusaurantiumL.Var.amara Engl..Have dispelling the stagnated QI, diffusing painful abdominal mass, rush down effects such as expectorant, removing food stagnancy.
Radix Et Rhizoma Rhei: this product contains Senna fruit glycoside, purging heat and dredging bowels, removing pathogenic heat from blood and toxic substance from the body, eliminating blood stasis and inducing menstruation.Radix Et Rhizoma Rhei contains anthracene derivative, glycosides compound, tannin class, organic acid, volatile oil etc.The effect that Radix Et Rhizoma Rhei has function of gallbladder promoting, protects the liver, and can promote pancreatic secretion, inhibition pancreatin activity, can resist gastric and duodenal ulcers simultaneously.Radix Et Rhizoma Rhei can make moisture content be trapped in enteric cavity and promote defecation, and hepatic injury is had significant protective effect, can promote bile secretion, and Radix Et Rhizoma Rhei can prevent the acute edema type that trypsin or ethanol bring out or the generation of acute hemorrhagic necrotizing pancreatitis.
Herba Artemisiae Scopariae: contain volatile oil, capillon and folic acid, significant function of gallbladder promoting, antiviral are arranged, protect the liver, infection, the effect that improves immunologic function.
Fructus Crataegi: this product contains organic acid such as citric acid, Crataegolic acid, chlorogenic acid, malic acid, in addition, contains carotene, vitamin, has cholesterol reducing, and enhance immunity is antibacterial, promotes the digestion of fatty food stagnation, increases the secretion of stomach digestive enzyme.Facilitating digestion, promoting digestion and removing stagnation, circulation of qi promoting dissipating blood stasis, the effect of relieving dyspepsia.
Massa Medicata Fermentata: this product contains volatile oil, protein, yeast, vitamin B complex etc., and it is by the oxidation energy supply of human body, and the promotion human body is digested and assimilated food protein, has digestion promoting, orectic effect.
Radix Gentianae: this product contains gentiopicrin, trilobatin, erythricine etc., and have protect the liver, the effect of function of gallbladder promoting, heat clearing and damp drying, elimination gastral cavilty distending pain, can reduce glutamate pyruvate transaminase, for various bacteria inhibitory action is arranged all.
Herba Lysimachiae: this product contains choline, potassium salt, volatile oil, aminoacid, lactone etc., and can promote bile to discharge from bile duct, has effects such as detumescence softening the hard mass, promoting the function of the gallbladder to alleviate jaundice, subduing swelling and detoxicating, calculus, for golden yellow Fructus Vitis viniferae ball inhibitory action is arranged.
Fructus Hordei Germinatus: compositions such as the starch-containing enzyme of this product, conversion carbohydrase, protein, fatty oil, vitamin B, have slight facilitation for gastric acid and pepsic secretion, have the effect of spleen benefiting and stimulating the appetite, promote qi circulation digestion promoting, dispersing the stagnated live-QI to relieve the stagnation of QI.
The Rhizoma Atractylodis Macrocephalae: this product contains volatile oil, atractylone, atractylol, vitamin A etc.Has the certain protection effect for the hepatic injury that has carbon tetrachloride to cause; can reduce hepatocellular degeneration necrosis; the glutamate pyruvate transaminase of rising is descended; prevent the minimizing of liver glycogen; be significantly increased choleresis; have and promote cellular immunization to improve antiviral ability, blood sugar lowering, antibacterial, protect the liver, function of gallbladder promoting, the spleen strengthening and damp drying, dyspepsia and intestinal stasis relieving, circulation of qi promoting remove effect full, clearing heat secreting bile.
With respect to medicine at first to file CNCN1364626A, the present invention has added the Rhizoma Atractylodis Macrocephalae and Fructus Hordei Germinatus on this basis again, thereby further alleviate the too concentrated side effect that is produced of the efficacy of a drug such as Herba Lysimachiae, Radix Gentianae and Radix Et Rhizoma Rhei in original prescription, the adding of the Rhizoma Atractylodis Macrocephalae and Fructus Hordei Germinatus simultaneously can also further improve the effect of hepatoprotective, enhance immunity, in addition, relatively pay attention to the equilibrium of consumption between each crude drug of medicament composing prescription of the present invention, the compatibility of various crude drug is brought out the best in each other, further the therapeutic effect that improves.
Following experimental data can confirm that medicine of the present invention has better effect with respect to the medicine of patent application CN1364626A formerly on therapeutical effect:
The comparison of experiment one, enhancing human body immunity effect and liver protection:
1, anti-hypoxia experiment: get 30 of white mouse, body weight 20～24g.Be divided into matched group at random, the medicine group of CN1364626A, medicine group of the present invention.Every group 10, male and female half and half, sub-cage rearing.With the conversion of people's conventional therapy dosage is the dosage of mice.The conversion formula is: tested animal is tried out the body surface area ratio of the body surface area ratio/known animal of dosage=known animals administer amount * tested animal.Control group administered physiological saline, 1 time/drip continuous 13.1h after the last administration, it is the 150ml port grinding bottle that mice is placed volume respectively, in put the 15g sodica calx, its time-to-live of airtight observation.The results are shown in Table 5.
The influence of table 5 pair mice normobaric hypoxia (X ± SD)
Annotate: compare with matched group:
*P＜0.01;
Compare with CN1364626A medicine group: #P＜0.05
CN1364626A medicine and medicine of the present invention all can improve mice normobaric hypoxia endurance, and mean survival time is than matched group significant prolongation (P＜0.01); Both compare, mean survival time also variant (P＜0.05).Illustrate: medicine of the present invention and CN1364626A medicine can both significantly improve mice normobaric hypoxia endurance, and the effect of medicine of the present invention is better than the medicine of CN1364626A.
2, protect the liver experiment: with reference to Zhang Juntian chief editor " modern pharmacology experimental technique " (volume two), combined publication society of China Concord Medical Science University of Beijing Medical University, the 1397-1398 page or leaf, disclosed method in " first segment chmice acute chemistry liver injury model ", set up the acute chemical liver injury model of mouse carbon tetrachloride, carry out the contrast of the medicine hepatoprotective effect of medicine of the present invention and CN1364626A.
The test grouping:
1, normal control group: animal is not cooked any processing, and normal physiological saline is irritated stomach
2, model control group: after the animal model modeling success, normal physiological saline is irritated stomach
3, CN1364626A medicine group: the 10mg/Kg body weight is irritated stomach
4, medicine group of the present invention: the 10mg/Kg body weight is irritated stomach
Following table has shown the influence of respectively organizing Mouse Liver function leading indicator GOT, GPT
| Group | Number of animals | GOT (active unit) | GPT (active unit) |
| The normal control group | 10 | 21.73±17.08 | 49.73±18.09 |
| Model control group | 10 | 259.74±79.73 | 299.79±56.82 |
| CN1364626A medicine group | 10 | 178.89±61.72 | 229.37±52.87 |
| Medicine group of the present invention | 10 | 81.73±27.82 | 117.75±48.73 |
This table shows that all there is significant difference (P＜0.05) in the medicine group with model control group, and also there are significant difference (P＜0.05) in medicine group of the present invention and CN1364626A medicine group, can prove that thus medicine of the present invention will obviously be better than CN1364626A medicine group on hepatoprotective effect.
The contrast of experiment two, cholecystitis therapeutic effect
Following test data is after prescription improves (2007), at the clinical trial statistical data of 2006 (CN1364626A medicine groups) and 2007-2008 (medicine group of the present invention):
Data show: the cure rate of CN1364626A medicine group (2006) is 84.19%, effective percentage is: 88.23%; The cure rate of medicine group of the present invention (2007) is 97.65%, effective percentage is: 99.22%; The cure rate of medicine group of the present invention (first half of the year in 2008) is: 97.18%, effective percentage is: 99.30%.Thereby proved that its cure rate and effective percentage all are significantly increased in the therapeutic process of medicine of the present invention at cholecystitis after improving.
Embodiment:
Embodiment 1:
Choose Radix Aucklandiae 20g, Radix Curcumae 25g, Fructus Aurantii 25g, Radix Et Rhizoma Rhei 10g, Herba Artemisiae Scopariae 50g, Fructus Hordei Germinatus (parched) 25g, Fructus Crataegi 30g, Massa Medicata Fermentata 25g, Radix Gentianae 15g, Herba Lysimachiae 20g, Rhizoma Atractylodis Macrocephalae (parched) 30g; Take by weighing above-mentioned materials of weight proportions medicine, the selected roguing of medical material, porphyrize is crossed 120 mesh sieves respectively, adds the auxiliary materials and mixing packing and makes powder.
Embodiment 2:
Take by weighing Radix Aucklandiae 10Kg, Radix Curcumae 15Kg, Fructus Aurantii 15Kg, Radix Et Rhizoma Rhei 5Kg, Herba Artemisiae Scopariae 30Kg, Fructus Hordei Germinatus (parched) 15Kg, Fructus Crataegi 20Kg, Massa Medicata Fermentata 15Kg, Radix Gentianae 10Kg, Herba Lysimachiae 10Kg, Rhizoma Atractylodis Macrocephalae (parched) 20Kg; With above-mentioned materials of weight proportions medicine, the selected roguing of medical material, the aqueous solution that adds 8 times of amounts soaked 10 hours, concentrated to make extractum, add an amount of dextrin, protein sugar, mix, pulverize mixing, granulate with 90% ethanol moistening, in 60 ℃ of dryings, granulate is made granule.
Embodiment 3:
Take by weighing Radix Aucklandiae 30g, Radix Curcumae 35g, Fructus Aurantii 35g, Radix Et Rhizoma Rhei 20g, Herba Artemisiae Scopariae 60g, Fructus Hordei Germinatus (parched) 35g, Fructus Crataegi 50g, Massa Medicata Fermentata 35g, Radix Gentianae 25g, Herba Lysimachiae 30g, Rhizoma Atractylodis Macrocephalae (parched) 50g; With above-mentioned materials of weight proportions medicine, the selected roguing of medical material, the alcoholic solution that adds 9 times of amounts extracted 8 hours, concentrated to make extractum, add adjuvants such as an amount of magnesium stearate, correctives, mix, pulverize mixing, granulate with 90% ethanol moistening, in 60 ℃ of dryings, granulate is made tablet.
Claims (2)
1. Chinese medicine that is used for the treatment of cholecystitis is characterized in that being made by following raw medicaments in portion by weight:
Radix Aucklandiae 10-30 weight portion, Radix Curcumae 15-35 weight portion, Fructus Aurantii 15-35 weight portion, Radix Et Rhizoma Rhei 5-20 weight portion, Herba Artemisiae Scopariae 30-60 weight portion, Fructus Hordei Germinatus (parched) 15-35 weight portion, Fructus Crataegi 20-50 weight portion, Massa Medicata Fermentata 15-35 weight portion, Radix Gentianae 10-25 weight portion, Herba Lysimachiae 10-30 weight portion, Rhizoma Atractylodis Macrocephalae (parched) 20-50 weight portion.
2. the Chinese medicine of treatment cholecystitis according to claim 1 is characterized in that the weight proportion of each crude drug is:
The Radix Aucklandiae 20 weight portions, Radix Curcumae 25 weight portions, Fructus Aurantii 25 weight portions, Radix Et Rhizoma Rhei 10 weight portions, Herba Artemisiae Scopariae 50 weight portions, Fructus Hordei Germinatus (parched) 25 weight portions, Fructus Crataegi 30 weight portions, Massa Medicata Fermentata 25 weight portions, Radix Gentianae 15 weight portions, Herba Lysimachiae 20 weight portions, Rhizoma Atractylodis Macrocephalae (parched) 30 weight portions.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101344557A CN101322826B (en) | 2008-07-25 | 2008-07-25 | Chinese medicine for treating cholecystitis and method of preparing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101344557A CN101322826B (en) | 2008-07-25 | 2008-07-25 | Chinese medicine for treating cholecystitis and method of preparing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101322826A CN101322826A (en) | 2008-12-17 |
| CN101322826B true CN101322826B (en) | 2010-08-25 |
Family
ID=40186626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008101344557A Expired - Fee Related CN101322826B (en) | 2008-07-25 | 2008-07-25 | Chinese medicine for treating cholecystitis and method of preparing the same |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101322826B (en) |
-
2008
- 2008-07-25 CN CN2008101344557A patent/CN101322826B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN101322826A (en) | 2008-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101537060B (en) | Medicine for treating AIDS | |
| CN102772778A (en) | Chinese medicinal composition for treating summer heat-dampness | |
| CN101036777A (en) | Oral Chinese traditional medicine composition for treating chronic enteritis | |
| CN106266463B (en) | Traditional Chinese medicine composition for treating hyperuricemia and application thereof | |
| CN102188685B (en) | Externally-applied traditional Chinese medicine powder for treating diarrhea type irritable bowel syndrome and preparation method thereof | |
| CN104984316A (en) | Medicine for treating female cold in uterus | |
| CN103055260A (en) | Traditional Chinese medicine composition for treating ulcerative colitis and preparation method thereof | |
| CN103920027A (en) | Medicament for treating acute jaundice hepatitis B and preparation method thereof | |
| CN111588828A (en) | Chinese medicinal preparation for treating new coronavirus and viral diseases, and its preparation method | |
| CN102488784A (en) | Traditional Chinese medicine composition for treating low back pain | |
| CN106692909A (en) | Pyrus pyrifolia tree viscum coloratum grease with lung-clearing and phlegm-eliminating effects | |
| CN102727693B (en) | Compound propolis composition used for treating swine toxoplasmosis, and preparation method thereof | |
| CN104547251B (en) | A kind of navel patch and preparation method for treating chordapsus | |
| CN102145099A (en) | Traditional Chinese medicine for treating infertility caused by liver stagnation | |
| CN101322826B (en) | Chinese medicine for treating cholecystitis and method of preparing the same | |
| CN105031595A (en) | Traditional Chinese medicine tablet for treating nummular eczema and preparing method thereof | |
| CN105213758A (en) | A kind of Chinese medicine composition for the treatment of chronic pneumonia and preparation method thereof | |
| CN105878716B (en) | A kind of Chinese herbal compound preparation for preventing and treating chicken hydropericardium syndrome | |
| CN101450132A (en) | Medicine for treating cancer | |
| CN101028421B (en) | Chinese medicine for treating chronic kidney failure | |
| CN1958028A (en) | Preparation of Chinese traditional medicine for treating hyperplasia of prostate | |
| CN107456551A (en) | A kind of Chinese medicine for treating gastritis | |
| CN103055090B (en) | Pure Chinese medicinal composition for treating fowl cholera and preparation method of pure Chinese medicinal composition | |
| CN103028028B (en) | Traditional Chinese medicine agent for treating primary hepatic carcinoma | |
| CN105833228A (en) | Drug preparation for reversing gastric cancer drug resistance and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| DD01 | Delivery of document by public notice |
Addressee: Zhang Zhaoxiang Document name: Notification of Termination of Patent Right |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100825 Termination date: 20140725 |
|
| EXPY | Termination of patent right or utility model |